scholarly journals The −202 A Allele of Insulin-Like Growth Factor Binding Protein-3 (IGFBP3) Promoter Polymorphism Is Associated with Higher IGFBP-3 Serum Levels and Better Growth Response to Growth Hormone Treatment in Patients with Severe Growth Hormone Deficiency

2009 ◽  
Vol 94 (2) ◽  
pp. 588-595 ◽  
Author(s):  
Everlayny Fiorot Costalonga ◽  
Sonir R. Antonini ◽  
Gil Guerra-Junior ◽  
Berenice Bilharinho Mendonca ◽  
Ivo J. P. Arnhold ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Growth Response ◽  
Growth Hormone Treatment ◽  
Serum Levels ◽  
Hormone Treatment ◽  
Promoter Polymorphism ◽  
Hormone Deficiency ◽  
Severe Growth ◽  
Igfbp 3

scholarly journals Factors affecting IGF-I level and correlation with growth response during growth hormone treatment in LG Growth Study

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0252283
Author(s):  
Ji Hyun Kim ◽  
Su Jin Kim ◽  
Jieun Lee ◽  
Choong Ho Shin ◽  
Ji-Young Seo
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Growth Response ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Hormone Deficiency ◽  
Growth Study ◽  
Korean Children ◽  
Factors Affecting ◽  
Igf I

Growth hormone treatment strategies to achieve the goal include the titration of GH doses according to serum insulin-like growth factor I (IGF-I) concentrations. However, IGF-I levels do not always correlate well with the growth response. This study aims to identify the factors affecting the IGF-I concentration and identify the relationship between IGF-I and the treatment response. The data of prepubertal children treated with recombinant human GH for more than one year were obtained from the LG Growth Study (LGS) Database. This study includes patients with idiopathic growth hormone deficiency (IGHD), organic growth hormone deficiency (OGHD), or Turner syndrome (TS) or small for gestational age (SGA). Among 2,021 participants registered in LGS, 366 subjects were selected, 252 had IGHD, 16 had OGHD, 31 had TS, and 67 were SGA. In the IGHD and SGA groups, IGF-I levels had a positive correlation with weight SDS. There was no significant relationship between the pre-treatment IGF-I level and growth response. However, in the IGHD group, the growth response was significantly higher when the change in the IGF-I SDS value was 1 or more (p = 0.0013). Therefore, IGF-I concentrations should be used as an indicator to monitor the treatment compliance rather than for efficacy determination in Korean children of short stature with GH treatment.

Growth hormone treatment during pregnancy in a growth hormone-deficient woman

1995 ◽  
Vol 132 (6) ◽  
pp. 727-729 ◽  
Author(s):  
Jørn Müller ◽  
Jørgen Starup ◽  
J Sandahl Christiansen ◽  
Jens OL Jøgensen ◽  
Anders Juul ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Abdominal Ultrasound ◽  
Serum Levels ◽  
Hormone Treatment ◽  
Donor Insemination ◽  
Gh Treatment ◽  
Igf I ◽  
Igf Binding ◽  
Igfbp 3

Müller J, Starup J, Christiansen JS, Jørgensen JOL, Juul A, Skakkebaek NE, Growth hormone treatment during pregnancy in a growth hormone-deficient woman. Eur J Endocrinol 1995;132:727–9. ISSN 0804–4643 Information on the course and outcome of pregnancies in growth hormone (GH)-deficient patients is sparse, and GH treatment during pregnancy in such women has not been described previously. We have studied fetal growth and serum levels of GH, insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3) during pregnancy, as well as birth weight and hormone levels after delivery in a 2 5-year-old woman with idiopathic, isolated GH deficiency diagnosed at the age of 7 years. As part of a clinical trial, the patient was treated with 2 IU/M2 GH for a period of 5 years. At this time she became pregnant after donor insemination. The GH treatment was continued until variant GH production from the placenta was evident. Serum levels of GH, IGF-I and IGFBP-3 were measured monthly during pregnancy after 3 days off GH therapy. Abdominal ultrasound was performed five times. Hormonal levels were measured immediately after delivery and during the following days. Serum GH and IGF-I levels increased during the second half of pregnancy: serum IGFBP-3 remained constant throughout pregnancy at a normal level. Serum levels of GH fell within 1 h after delivery, and levels of IGF-I and IGFBP-3 decreased into the range of GH-deficient women 4 days after. The fetal biparietal diameter increased normally, and birthweight was 3.564kg, length 52 cm. No adverse events were recorded. We conclude that the role of GH replacement during pregnancy of GH-deficient women should be investigated further. Jørn Müller, Department of Growth and Reproduction, GR 5064, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen ø, Denmark

Sign in / Sign up

Export Citation Format

Share Document